Incidence and severity of reactogenicity through Day 7 and adverse events (AEs) through end of study (Phase 2);Incidence of SAEs and medically-attended AEs (Phase 2);Incidence of symptomatic, virologically confirmed COVID-19 (Phase 3);Occurrence of changes from baseline in physical examination, vital signs, and clinical safety laboratory values (Phase 2)

Incidence and severity of reactogenicity through Day 7 and adverse events (AEs) through end of study (Phase 2);Incidence of SAEs and medically-attended AEs (Phase 2);Incidence of symptomatic, virologically confirmed COVID-19 (Phase 3);Occurrence of changes from baseline in physical examination, vital signs, and clinical safety laboratory values (Phase 2)